Fonte: Clinical rheumatology. Unidade: FM
Assuntos: AUTOANTICORPOS, FÁRMACOS IMUNOSSUPRESSORES, VIMENTINA, ÍNDICE DE GRAVIDADE DA DOENÇA
ABNT
DINIS, Valquiria G et al. Abatacept induced long-term non-progressive reduction in gamma-globulins and autoantibodies: dissociation from disease activity control. Clinical rheumatology, v. 39, n. 6, p. 1747-1755, 2020Tradução . . Disponível em: https://doi.org/10.1007/s10067-020-04932-9. Acesso em: 12 set. 2024.APA
Dinis, V. G., Viana, V. T., Leon, E. P., Silva, C. A. A. da, Saad, C. G., Moraes, J. C., et al. (2020). Abatacept induced long-term non-progressive reduction in gamma-globulins and autoantibodies: dissociation from disease activity control. Clinical rheumatology, 39( 6), 1747-1755. doi:10.1007/s10067-020-04932-9NLM
Dinis VG, Viana VT, Leon EP, Silva CAA da, Saad CG, Moraes JC, Bonfa ESD de O, Medeiros-ribeiro AC. Abatacept induced long-term non-progressive reduction in gamma-globulins and autoantibodies: dissociation from disease activity control [Internet]. Clinical rheumatology. 2020 ; 39( 6): 1747-1755.[citado 2024 set. 12 ] Available from: https://doi.org/10.1007/s10067-020-04932-9Vancouver
Dinis VG, Viana VT, Leon EP, Silva CAA da, Saad CG, Moraes JC, Bonfa ESD de O, Medeiros-ribeiro AC. Abatacept induced long-term non-progressive reduction in gamma-globulins and autoantibodies: dissociation from disease activity control [Internet]. Clinical rheumatology. 2020 ; 39( 6): 1747-1755.[citado 2024 set. 12 ] Available from: https://doi.org/10.1007/s10067-020-04932-9